Please login to the form below
Takecab
This page shows the latest Takecab news and features for those working in and with pharma, biotech and healthcare.
Biologics set to revolutionise the gastrointestinal market
Also contributing to the predicted market growth are recent product approvals such as Takeda's Takecab (vonoprazan) for gastroesophageal reflux disease, and Entvio (vedolizumab) for IBD.
Latest news
-
Rare disease therapies head the ‘class of 2015’
Baxalta. USA. vonoprazan fumarate. Takecab. acid-related diseases. potassium-competitive acid blocker. Takeda/Otsuka.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sinovac reveals positive preliminary data for COVID-19 vaccine
- How will the events and exhibitions industry change post-Coronavirus?
- Finalists 2020 - Communiqué Awards
- Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
- Syneos Health appoints trio of senior hires
- Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus
PMHub
Page & Page
For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...
Latest intelligence
- The search for treatments for Parkinson’s disease
- The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
- Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
- Ditch the Label – it’s just me....
- The impact of COVID-19 on clinical trials
- As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...
Quick links
Infographics
